{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:11:04Z","timestamp":1791389464288,"version":"4.3.3"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jaad.2025.10.030","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:54:54Z","timestamp":1760100894000},"page":"810-818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tolerability and efficacy of unorthodox dosing regimens of tofacitinib and baricitinib in pediatric patients with moderate to severe alopecia areata"],"prefix":"10.1016","volume":"94","author":[{"given":"Mei","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanlan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunjian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2025.10.030_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/jamadermatol.2023.4661","article-title":"Alopecia areata","volume":"160","author":"Gaurav","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.10.030_bib2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/bjd\/ljae058","article-title":"Global, regional and national epidemiology of alopecia areata: a systematic review and modelling study","volume":"191","author":"Jeon","year":"2024","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.10.030_bib3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s13555-023-00946-8","article-title":"Review on alopecia areata in the Middle East and Africa: landscape and unmet needs","volume":"13","author":"Al","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"10.1016\/j.jaad.2025.10.030_bib4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","article-title":"Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis","volume":"82","author":"Lee","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.10.030_bib5","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/jdv.15927","article-title":"'The psychosocial burden of alopecia areata and androgenetica': a cross-sectional multicentre study among dermatological out-patients in 13 European countries","volume":"34","author":"Titeca","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2025.10.030_bib6","article-title":"Prevalence and burden of vitiligo in Africa, the Middle East and Latin America","volume":"4","author":"Al","year":"2024","journal-title":"Skin Health Dis"},{"issue":"2","key":"10.1016\/j.jaad.2025.10.030_bib7","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/jocd.14122","article-title":"Psychiatric basics of alopecia areata in pediatric patients: evaluation of emotion dysregulation, somatization, depression, and anxiety levels","volume":"21","author":"Altunisik","year":"2022","journal-title":"J Cosmet Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.10.030_bib8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ajd.12941","article-title":"Treatment of alopecia areata: an Australian expert consensus statement","volume":"60","author":"Cranwell","year":"2019","journal-title":"Australas J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2025.10.030_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1500973","article-title":"Pharmacologic inhibition of JAK-STAT signaling promotes hair growth","volume":"1","author":"Harel","year":"2015","journal-title":"Sci Adv"},{"key":"10.1016\/j.jaad.2025.10.030_bib10","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/jdv.20526","article-title":"Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: results from the ALLEGRO-LT phase 3, open-label study","volume":"39","author":"Tziotzios","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2025.10.030_bib11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaad.2018.08.041","article-title":"Tofacitinib for the treatment of alopecia areata in preadolescent children","volume":"80","author":"Craiglow","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.10.030_bib12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"issue":"2","key":"10.1016\/j.jaad.2025.10.030_bib13","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/bjd\/ljac059","article-title":"Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials","volume":"188","author":"King","year":"2023","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.10.030_bib14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/bjd\/ljad118","article-title":"Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib","volume":"189","author":"Asfour","year":"2023","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.10.030_bib15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2)","volume":"24","author":"Kwon","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"10387","key":"10.1016\/j.jaad.2025.10.030_bib16","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jaad.2025.10.030_bib17","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1111\/jocd.15425","article-title":"Efficacy and safety of tofacitinib for treatment of alopecia areata in children: a systematic review and meta-analysis","volume":"21","author":"Behrangi","year":"2022","journal-title":"J Cosmet Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.030_bib18","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/psp4.13131","article-title":"A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis","volume":"13","author":"Decker","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"10.1016\/j.jaad.2025.10.030_bib19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s11136-022-03170-7","article-title":"Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata","volume":"32","author":"Wyrwich","year":"2023","journal-title":"Qual Life Res"},{"issue":"5","key":"10.1016\/j.jaad.2025.10.030_bib20","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40257-020-00545-9","article-title":"Development of clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata","volume":"21","author":"Wyrwich","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2025.10.030_bib21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ced\/llae320","article-title":"Assessment of clinician-reported outcome measures for alopecia areata: a systematic scoping review","volume":"50","author":"Darchini-Maragheh","year":"2025","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.030_bib22","doi-asserted-by":"crossref","first-page":"e770","DOI":"10.1111\/jdv.18885","article-title":"Long-term patient-reported perception and experience of methylprednisolone pulse with or without methotrexate in alopecia areata: a French retrospective single-centre cohort","volume":"37","author":"Guillaume","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2025.10.030_bib23","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/jdv.19665","article-title":"Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2","volume":"38","author":"Senna","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.jaad.2025.10.030_bib24","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2025.10.030_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata","volume":"13","author":"Lensing","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jaad.2025.10.030_bib26","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.jaad.2025.10.030_bib27","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2025.10.030_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1372810","article-title":"Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis","volume":"15","author":"Yan","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jaad.2025.10.030_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","article-title":"Tofacitinib for the treatment of alopecia areata and variants in adolescents","volume":"76","author":"Craiglow","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.10.030_bib30","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jaad.2016.11.038","article-title":"Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis","volume":"76","author":"Castelo-Soccio","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.10.030_bib31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","article-title":"Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program","volume":"25","author":"King","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2025.10.030_bib32","series-title":"Baricitinib provides significant hair regrowth in adolescents with severe alopecia areata: 36-week efficacy and safety results from a phase 3 randomized, controlled trial. Paper presented at: American Academy of Dermatology Annual Meeting","author":"Passeron","year":"2025"},{"issue":"2","key":"10.1016\/j.jaad.2025.10.030_bib33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"15","key":"10.1016\/j.jaad.2025.10.030_bib34","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy","year":"2016","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.jaad.2025.10.030_bib35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12969-017-0212-y","article-title":"Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study","volume":"15","author":"Ruperto","year":"2017","journal-title":"Pediatr Rheumatol Online J"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225029834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225029834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:37:31Z","timestamp":1771393051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225029834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0190962225029834"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.10.030","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerability and efficacy of unorthodox dosing regimens of tofacitinib and baricitinib in pediatric patients with moderate to severe alopecia areata","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.10.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}